title: Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
abstract: To compare the outcomes of the first intradetrusor injections of abobotulinum toxin 750 U and onabotulinum toxin 200 and 300 U in patients with neurogenic detrusor overactivity (NDO).
  
  
  
  A retrospective case-control study was conducted including 211 NDO patients treated in three consecutives eras with onabotulinum toxin 300 U (2004-2006; 80 patients), abobotulinum toxin 750 U (2007-2011; 78 patients) or onabotulinum toxin 200 U (2011-2014; 53 patients). Urodynamic and clinical parameters were compared between groups. The primary endpoint was the rates of success defined as the combination of urgency, urinary incontinence, and detrusor overactivity resolution.
  
  
  
  When comparing abobotulinum toxin to onabotulinum toxin any doses (200 or 300 U; n = 133), success rates were similar (65.4% vs. 55.6%; P = 0.16). Patients treated with abobotulinum toxin 750 U had higher success rate (65.4% vs. 41.5%; P = 0.007) compared to those who received onabotulinum toxin 200 U. In contrast, there were similar success rates in abobotulinum toxin 750 U and onabotulinum toxin 300 U groups (65.4% vs. 65%; P = 0.91) but with a trend towards longer interval between the first and the second injection in the onabotulinum toxin 300 U group (12.4 vs. 9.3 months; P = 0.09).
  
  
  
  Intradetrusor injections of abobotulinum toxin 750 U for NDO provided better outcomes than injections of onabotulinum toxin 200 U. Success rates of abobotulinum toxin 750 U and onabotulinum toxin 300 U were similar but interval between injections tended to be longer with onabotulinum toxin 300 U. Neurourol. Urodynam. 36:734-739, 2017. © 2016 Wiley Periodicals, Inc.
authors.affiliation: Service d'Urologie, CHU Rennes, Rennes, France.|Equipe thématique INPHY CIC 1414 et INSERM UMR 991, CHU Rennes, Rennes, France.|Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Peyronnet
authors.affiliation: Service de Médecine Physique et Réadaptation, CHU Rangueil, Toulouse, France.
authors.forename: Evelyne
authors.initials: E
authors.lastname: Castel-Lacanal
authors.affiliation: Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Roumiguie
authors.affiliation: Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Even
authors.affiliation: Service de Médecine Physique et Réadaptation, CHU Rangueil, Toulouse, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Marque
authors.affiliation: Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Soulié
authors.affiliation: Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Rischmann
authors.affiliation: Département d'Urologie, Transplantation Rénale et Andrologie, CHU Rangueil, Toulouse, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Game
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA
keywords: abobotulinum toxin; botulinum toxin; detrusor overactivity; neurogenic bladder; onabotulinum toxin